Inventor · disambiguated record
Marco Ruella
Also filed as: RUELLA MARCO
15 granted patents·20 pending applications·226 citations·filing 2015–2024
93Inventor score
Top patents by PatentIndex Score
35 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0396US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0495US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0595US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 0694US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 0794US11026976B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·6 cites·23 claims
- 0893US11872249B2Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domainNOVARTIS AG·Filed 2021·Granted Jan 16, 2024·2 cites·38 claims
- 0989US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 1087US11673964B2Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemiasUNIV PENNSYLVANIA·Filed 2019·Granted Jun 13, 2023·2 cites·20 claims
- 1186US12227588B2Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemiasUNIV PENNSYLVANIA·Filed 2024·Granted Feb 18, 2025·0 cites·22 claims
- 1283US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 1380US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1479USRE49847ENucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2022·Granted Feb 27, 2024·0 cites·35 claims
- 1579US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1677US2023331864A1Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and LeukemiasUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1776US2025163148A1Anti-car compositions and methodsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1874US2024271090A1CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell TherapyUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1970US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 2070US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 2170US2024408206A1Compositions and methods for treating b-lymphoid malignanciesNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2264US2024392023A1Anti-cd30 antibody and chimeric antigen receptor comprising thereofABCLON INC·Filed 2023·Application pending·0 cites
- 2363US2025064852A1CD5 Modified Cells Comprising Chimeric Antigen Receptors (CARs) for Treatment of Solid TumorsUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 2462US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2562US2024335539A1Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacyUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 2661US2024293481A1Methods and compositions for predicting cancer survival and car t cell toxicityMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2024·Application pending·0 cites
- 2761US2020080056A1CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell TherapyUNIV PENNSYLVANIA·Filed 2019·Application pending·0 cites
- 2861US2021179709A1Anti-car compositions and methodsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 2957US2024376197A1Compositions and methods for chimeric antigen receptors specific to b cell receptorsUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3056US2025060368A1Methods of detecting and treating immunotherapy-resistant cancerWASHINGTON UNIVERSITY ST LOUIS·Filed 2023·Application pending·0 cites
- 3152US2020376035A1Methods and compositions comprising cart and a smac mimeticUNIV PENNSYLVANIA·Filed 2019·Application pending·0 cites
- 3247US2021213063A1Combination therapy with chimeric antigen receptor (car) therapiesNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3342US2019161542A1Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage moleculeNOVARTIS AG·Filed 2017·Application pending·0 cites
- 3440US2019336504A1Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitorGILL SAAR·Filed 2017·Application pending·0 cites
- 3533US2018140602A1Combination of chimeric antigen receptor therapy and amino pyrimidine derivativesANGST DANIELA·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →